Chronic Lymphocytic Leukemia

Clinical study results presented at the 2013 American Society of Clinical Oncology Annual Meeting may offer new hope for patients with chronic lymphocytic leukemia.

Jennifer Woyach, MD, discusses Bruton's tyrosine kinase inhibition and the mechanism of action of ibrutinib.

At the 18th Annual Conference of the National Comprehensive Cancer Network (NCCN), experts presented the latest updates to the NCCN Clinical Practice Guidelines in Oncology.

Ibrutinib was well tolerated and highly effective in eradicating tumor cells in both treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia.

The FDA has received a new drug application for ibrutinib as a therapy for previously treated CLL and previously treated MCL.

Edward Bradley, MD, gives an overview of the mechanism of action and development of moxetumomab pasudotox, a monoclonal antibody directed at CD22.

Patients with chronic lymphocytic leukemia (CLL) and patients with mantle cell lymphoma (MCL) showed high response rates to therapy with ibrutinib.

A phase I study found that idelalisib produced rapid and prolonged tumor shrinkage in half of patients with relapsed or refractory CLL who received the drug as monotherapy.

Working in a laboratory at the National Institutes of Health, Benjamin W. Purow, MD, became the first researcher to demonstrate that the Notch pathway plays a role in gliomas.

Francesco Lo-Coco, MD, Hematology, University Tor Vergata, speaks at the 2012 American Society of Hematology annual meeting about the use of arsenic trioxide in acute promyelocytic leukemia.

While there is no standard treatment for most patients with chronic lymphocytic leukemia who are age 65 years and older, several regimens are being tested in clinical trials.

Researchers have determined that high expression of microRNA-155 was associated with a poorer prognosis in patients with AML and that inhibition of a molecule that regulates the microRNA may serve as a therapeutic target for these patients.

Acute myeloid leukemia (AML), the most common acute form of leukemia in adults, is potentially driven by at least one genetic mutation in nearly all cases.

Implementation of a pharmacist-led glycemic control team was associated with improved glycemic control and utilization outcomes in a population of noncritically ill surgical patients.

Pamela Crilley, DO, explains the benefits and downfalls of prescribing tyrosine kinase inhibitors for the treatment of CML.